Security Snapshot

Akebia Therapeutics, Inc. - COMMON STOCK (AKBA) Institutional Ownership

CUSIP: 00972D105

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

169

Shares (Excl. Options)

101,696,929

Price

$1.39

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COMMON STOCK
Symbol
AKBA on Nasdaq
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
101,696,929
Latest holder snapshot 5 signals
Total 13F value
$141,405,505
Portfolio coverage rank
0%
Share change
-15,809,229
Value change
-$23,300,220
Number of holders
169
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
270,093,163
SEC-reported price per share
$1.16
Insider filing price
$1.16
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • AKBA - Akebia Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 00972D105.
  • 169 institutions reported positions in Q1 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 165 to 169 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $190,384,320 to $141,405,505.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 169 institutions filings for Q1 2026.

Open SEC evidence

Security key

00972D105

Latest holder period

Q1 2026

13F holders

169

13D/G owners

3

CIK / CUSIP context first

Open Q1 2026 holders AKBA full holder history Akebia Therapeutics, Inc. SEC filings Akebia Therapeutics, Inc. company facts Akebia Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
AKBA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% +18% $30,943,909 +$6,565,662 19,219,819 +27% BlackRock, Inc. 31 Dec 2025
STATE STREET CORP 4.3% -18% $16,027,328 -$2,861,506 11,614,006 -15% STATE STREET CORPORATION 31 Mar 2026
Satter Muneer A 2.6% $13,105,226 5,747,906 Satter Muneer A 31 Dec 2024

As of 31 Mar 2026, 169 institutional investors reported holding 101,696,929 shares of Akebia Therapeutics, Inc. - COMMON STOCK (AKBA). This represents 38% of the company’s total 270,093,163 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
32%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.9% 18,693,296 -3.2% 0% $25,983,682
STATE STREET CORP 4.3% 11,614,006 -15% 0% $16,143,468
VANGUARD CAPITAL MANAGEMENT LLC 4.1% 11,166,710 0% 0% $15,521,727
GEODE CAPITAL MANAGEMENT, LLC 2.4% 6,452,252 +2.8% 0% $8,970,938
GOLDMAN SACHS GROUP INC 1.3% 3,602,827 -23% 0% $5,007,930
CITIGROUP INC 1.1% 2,854,586 +17% 0% $3,967,875
BANK OF AMERICA CORP /DE/ 1% 2,763,362 +22% 0% $3,841,073
Qube Research & Technologies Ltd 0.89% 2,395,215 -20% 0% $3,329,349
MILLENNIUM MANAGEMENT LLC 0.88% 2,384,713 +44% 0% $3,314,751
VANGUARD PORTFOLIO MANAGEMENT LLC 0.82% 2,215,441 0% 0% $3,079,463
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.75% 2,015,577 -7.6% 0% $2,801,652
Nantahala Capital Management, LLC 0.74% 2,000,000 0% 0.17% $2,780,000
NORTHERN TRUST CORP 0.72% 1,945,586 -16% 0% $2,704,364
RENAISSANCE TECHNOLOGIES LLC 0.68% 1,833,128 -49% 0% $2,548,048
AQR CAPITAL MANAGEMENT LLC 0.66% 1,792,620 +177% 0% $2,491,742
VANGUARD FIDUCIARY TRUST CO 0.66% 1,779,301 0% 0% $2,473,228
JANE STREET GROUP, LLC 0.54% 1,456,674 +111% 0% $2,024,777
CITADEL ADVISORS LLC 0.51% 1,390,067 -70% 0% $1,932,194
ACADIAN ASSET MANAGEMENT LLC 0.51% 1,377,068 -37% 0% $1,909,000
FMR LLC 0.49% 1,335,328 +19% 0% $1,856,107
TWO SIGMA INVESTMENTS, LP 0.48% 1,297,801 +1332% 0% $1,803,943
HRT FINANCIAL LP 0.36% 976,937 -40% 0% $1,357,000
DIMENSIONAL FUND ADVISORS LP 0.34% 921,923 -41% 0% $1,280,467
UBS Group AG 0.28% 769,471 -12% 0% $1,069,564
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.27% 722,119 +11% 0% $1,003,745

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 101,696,929 $141,405,505 -$23,300,220 $1.39 169
2025 Q4 118,251,483 $190,384,320 -$16,096,783 $1.61 165
2025 Q3 123,669,076 $337,684,321 +$36,363,104 $2.73 176
2025 Q2 108,291,108 $394,183,978 +$56,486,637 $3.64 157
2025 Q1 95,246,755 $182,865,666 +$63,362,812 $1.92 142
2024 Q4 67,845,406 $128,903,910 +$16,367,542 $1.90 120
2024 Q3 59,433,206 $78,446,645 +$886,944 $1.32 113
2024 Q2 56,272,261 $57,424,732 -$2,482,254 $1.02 100
2024 Q1 56,991,509 $104,293,412 +$2,027,480 $1.83 108
2023 Q4 54,644,403 $67,756,919 +$4,503,736 $1.24 83
2023 Q3 50,796,845 $57,906,145 +$685,292 $1.14 72
2023 Q2 50,244,290 $45,972,433 -$1,392,343 $0.92 76
2023 Q1 51,839,170 $29,049,633 -$98,488 $0.56 62
2022 Q4 52,253,997 $30,149,698 +$763,514 $0.58 70
2022 Q3 52,161,214 $16,491,885 -$1,812,681 $0.32 79
2022 Q2 57,164,176 $20,180,226 -$11,164,741 $0.35 82
2022 Q1 81,183,875 $58,271,372 -$32,826,439 $0.72 115
2021 Q4 96,816,883 $218,731,670 -$6,193,557 $2.26 128
2021 Q3 98,493,468 $283,669,170 -$32,502,791 $2.88 119
2021 Q2 106,173,637 $402,396,029 +$22,237,368 $3.79 131
2021 Q1 100,546,584 $340,303,134 -$8,611,368 $3.38 134
2020 Q4 103,249,738 $289,096,531 -$2,381,228 $2.80 134
2020 Q3 100,173,386 $251,381,270 -$415,118,712 $2.51 155
2020 Q2 111,597,128 $1,515,160,970 +$263,628,807 $13.58 184
2020 Q1 92,760,043 $703,124,581 +$65,005,544 $7.58 150
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .